LATAM MedTech Insights

Brazil just added a complex new layer to its AI MedTech regulations. Last week, the Federal Council of Medicine (CFM) issued Resolution 2,454, a framework that directly impacts how physicians can use AI tools. This isn't about device registration through ANVISA; it's about winning the trust and acceptance of the end-users—the doctors themselves. This episode dives deep into what this resolution means for foreign MedTech innovators. We explore how this new ethical and governance-focused oversight creates a dual-approval landscape where both regulatory bodies and medical associations hold the keys to market access. We break down the unwritten rules and hidden challenges that your company will now face in Latin America's largest market. Imagine your AI-powered diagnostic software, already successful in Europe, is being trialed in a major São Paulo hospital. Suddenly, the clinical lead halts the trial. The reason? Your firm can't produce a satisfactory governance report detailing how the AI's algorithms align with the CFM's new ethical guidelines, creating a market-access roadblock that no one saw coming. In this episode, you will learn: - What are the crucial differences between ANVISA's requirements and the CFM's new AI resolution? - Why might your international clinical data be insufficient to gain physician trust in Brazil? - How does a doctor's new "right of refusal" for AI tools change your market entry strategy? - Is this new resolution a hidden barrier or an opportunity to build a stronger competitive moat? - What kind of local data and governance documentation do you now need to prepare? - How can you proactively engage with Brazil's medical community to ensure adoption? - What are the three key steps to de-risk your AI MedTech launch in this new environment? Struggling to keep up with shifting regulations in LATAM? At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise and advanced AI tools to streamline your market access. From acting as your local representative in Brazil to compiling technical dossiers with our AI platform, we turn regulatory hurdles into market opportunities. Don't let compliance challenges slow your growth. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure your foothold in Latin America.

This week on LATAM MedTech Insights, we dissect the breaking news from Brazil. ANVISA has unexpectedly tightened its cybersecurity regulations for Software as a Medical Device (SaMD), creating significant new challenges for foreign manufacturers. We explore the specific documentation now required and what this means for anyone trying to enter Latin America's largest market. This move signals a major shift in the region's regulatory philosophy, moving away from simple adoption of global standards towards hyper-local requirements tied to national laws like the LGPD. We analyze the immediate impact on companies with pending applications, using a real-world example of a European company whose market entry is now stalled, facing unforeseen costs and significant delays. Key Questions Answered: - What specific cybersecurity evidence does ANVISA now demand beyond FDA or CE Mark documentation? - How does Brazil's data privacy law (LGPD) create unique compliance risks for MedTech manufacturers? - Why is a global cybersecurity plan now insufficient for a successful Brazilian market submission? - What are the most common pitfalls leading to deficiency letters from ANVISA for SaMD products? - Are other LATAM countries like Mexico and Colombia expected to follow Brazil's lead? - How can you turn this complex new regulatory hurdle into a competitive advantage? - What should be included in a post-market surveillance plan to satisfy these new requirements? Navigating sudden regulatory shifts is what we do best. Pure Global offers end-to-end regulatory consulting, leveraging local expertise and advanced AI tools to streamline your market access. Whether it's developing a new regulatory strategy, compiling technical dossiers, or acting as your local representative, we ensure you stay ahead of the curve. Don't let regulatory surprises derail your LATAM expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

This week, we dissect a game-changing announcement from Brazil's ANVISA: a new "fast-track" approval process for AI-powered medical devices. While it promises rapid market access, it hides significant challenges beneath the surface that could derail unprepared international companies. This episode explores how Brazil's stringent data privacy law, the LGPD, is interwoven into this new regulatory pathway. We reveal why your existing global compliance frameworks might be insufficient and what specific steps are necessary to successfully navigate this complex but promising opportunity in Latin America's largest MedTech market. **Case Study:** Learn from the missteps of a European AI-diagnostic firm that saw its "fast-track" submission in Brazil stall due to unforeseen data validation requirements and non-compliance with local data privacy nuances, turning a promising opportunity into a costly delay. **This week's key questions:** - What specific device classes are eligible for ANVISA's new AI fast-track? - How does Brazil's LGPD law create unique compliance traps for foreign MedTech firms? - Why might your existing clinical data be rejected by Brazilian regulators? - What are the three biggest mistakes companies make when entering this new pathway? - Is the fast-track a genuine opportunity or a resource drain for non-specialists? - How can a local regulatory partner de-risk your entire market entry strategy? Pure Global offers end-to-end regulatory consulting solutions for Medical Technology (MedTech) and In-Vitro Diagnostic (IVD) companies, combining local expertise with advanced AI and data tools to streamline global market access. Contact Pure Global at info@pureglobal.com or visit us at https://pureglobal.com/.

Last week, Brazil's regulatory agency, ANVISA, issued an unexpected technical guidance that reclassifies certain Software as a Medical Device (SaMD) products. This move has sent shockwaves through the digital health sector, pushing many devices that rely on predictive algorithms into higher-risk categories overnight, invalidating existing registrations. In this episode of LATAM MedTech Insights, we break down what this clarification means for manufacturers, the new clinical evidence required for compliance under RDC 751, and why this signals a major strategic shift in Brazil's approach to digital health regulation. We explore the immediate commercial impact and the long-term strategic adjustments companies must now consider. Case in Point: Imagine your popular diabetes management app was approved as a Class II device. Suddenly, ANVISA's new interpretation of its predictive algorithm makes it a Class III product. Your registration is now invalid, marketing must cease, and you face the monumental task of generating local clinical data for a completely new submission. This is the exact challenge facing companies in Brazil right now. This episode's key questions: - How can a simple "technical guidance" invalidate your existing product registration in Brazil? - What specific software functions are now considered high-risk by ANVISA? - Is your current technical dossier prepared for this new level of scrutiny? - Why is relying on your existing EU or FDA clearance no longer enough for the Brazilian market? - What are the immediate steps you must take if your SaMD product is affected? - How does this change impact the market entry strategy for new digital health products in LATAM? - Could this regulatory pattern be replicated in other key LATAM markets? Feeling overwhelmed by the shifting regulatory landscape? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We combine local expertise in over 30 markets, including Brazil, with advanced AI tools to streamline global market access and ensure you stay compliant. Don't let regulatory surprises derail your strategy. Contact us for a consultation at info@pureglobal.com or visit https://pureglobal.com/.

This week on LATAM MedTech Insights, we dive into the significant new regulatory guidance from Brazil's ANVISA that is reshaping the landscape for Software as a Medical Device (SaMD). This update brings Brazil closer to global standards but introduces critical new challenges for foreign manufacturers in areas like risk classification, AI validation, and cybersecurity. We explore the immediate impact on MedTech companies aiming for the Brazilian market. For example, a US-based digital health firm was on the verge of submitting its product for approval. Now, they're confronting the painful reality that their AI algorithm's validation data is insufficient under the new, stricter guidelines, forcing them into a costly and time-consuming redevelopment cycle just to meet compliance. This episode unpacks how to anticipate and navigate these exact scenarios. Key Takeaways: - What are the three most critical changes in ANVISA's new SaMD framework? - How will the new risk classifications impact your product's path to market? - Are your cybersecurity measures compliant with both ANVISA's new rules and Brazil's LGPD? - What new clinical evidence is required for AI and machine learning-driven SaMD? - How can you leverage your existing international dossiers for the new submission process? - Why might your previous go-to-market strategy for Brazil now be obsolete? - What is the single biggest mistake companies make when interpreting new ANVISA guidance? Navigating evolving regulatory landscapes is our expertise. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using local experts and advanced AI tools to streamline market access in over 30 countries, including Brazil. From regulatory strategy and dossier submission to acting as your local in-country representative, we turn complexity into clarity. Don't let regulatory hurdles derail your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn more.

This week, we dive into a major regulatory shift in Brazil that just went live on March 1st, 2026. ANVISA's new Normative Instruction N°426/2026 activates the national UDI (Unique Device Identification) database, requiring manufacturers to submit detailed product data before entering the market. This episode breaks down the new requirements, the critical phased deadlines for different device classes, and the strategic implications for MedTech companies aiming to succeed in Latin America's largest market. We explore the hidden complexities, such as the absolute need for data equivalence between your ANVISA registration and your UDI submission. Consider the case of a cardiac stent manufacturer whose multi-million dollar product launch is completely stalled because of a single data mismatch in the new system. This highlights how a small administrative detail can become a major commercial barrier. Key Questions for This Episode: - Brazil's new UDI system just went live; are you prepared for the aggressive, risk-based deadlines? - What are the most common data mismatches that can block your market access? - Should you manage complex UDI submissions in-house or delegate them to a local Brazilian partner? - How does ANVISA's new database compare to the UDI systems in the US and Europe? - What is the single most critical step to take before submitting your first UDI record to ANVISA? - Are your current data management systems robust enough for this new era of traceability? - How can you leverage your Brazil Registration Holder to streamline this new compliance burden? At Pure Global, we specialize in turning these regulatory challenges into market opportunities. With our deep local expertise in Brazil and advanced AI-driven data tools, we provide end-to-end regulatory consulting to ensure your market access is seamless and compliant. We act as your local representative, manage technical dossier submissions, and navigate complex requirements like the new UDI system. To streamline your entry into Brazil and over 30 other global markets, contact us at info@pureglobal.com or visit https://pureglobal.com/.

This episode of LATAM MedTech Insights, brought to you by Pure Global, dives into the landmark regulatory shift just implemented by Brazil's ANVISA. We unpack the new RDC 830/2023 resolution for In-Vitro Diagnostic (IVD) devices, a critical update that redefines market access and compliance in Latin America's largest market. We explore how this harmonization with global standards impacts everything from risk classification to technical documentation. More importantly, we reveal the new strategic 'reliance pathway' that could dramatically accelerate your product's journey to market. Imagine your high-risk diagnostic device, facing a potential year-long review, suddenly becoming eligible for an expedited process in just a few months. This is now a reality for companies with existing approvals from major global authorities, but only if you know how to navigate the new system. Key questions answered in this episode: - What are the specific changes in ANVISA's new RDC 830/2023 for IVDs? - How do I determine if my IVD product's risk class has changed in Brazil? - What is the new 'reliance pathway' and which country approvals make me eligible? - How can leveraging my FDA or Health Canada approval cut my Brazilian registration time by over 70%? - What are the immediate steps my company must take to ensure compliance and avoid market access delays? - Does this change make Brazil a more attractive or more difficult market for IVD manufacturers? At Pure Global, we specialize in turning these complex regulatory updates into clear, actionable strategies. With local experts in Brazil and advanced AI tools, we manage the entire registration lifecycle, helping you leverage new pathways to gain a competitive edge. To ensure your company is prepared for the new era of IVD regulation in Brazil, contact us at info@pureglobal.com or visit https://pureglobal.com/.

A seismic regulatory shift is underway in Brazil, Latin America's biggest MedTech market. ANVISA's new Unique Device Identification (UDI) system, detailed in Normative Instruction 426/2026, is now being implemented. This isn't just a new labeling rule; it's a complex data management and submission challenge that could become a major barrier to market entry for unprepared device manufacturers. This episode breaks down exactly what the new requirements mean for your business. We go beyond the surface-level announcements to explore the practical, operational hurdles you will face. We discuss the critical importance of the SIUD database, the staggered compliance deadlines for different device classes, and why your existing global UDI strategy might not be enough for Brazil. Consider this: A successful European device company planned a major launch in Brazil, only to be halted for six months. The reason was not their product's quality, but their inability to provide the specific data attributes required by the new SIUD database, a detail they completely overlooked. This episode is designed to help you avoid that costly mistake. Key Takeaways: * What is Brazil's Normative Instruction 426/2026, and why is it a game-changer for market access? * How does the new SIUD database fundamentally alter device traceability requirements? * Are your data management systems prepared for the specific submission formats ANVISA demands? * What are the staggered compliance deadlines, and which one applies to your device portfolio? * Why is simply having a UDI on your label completely insufficient for the Brazilian market? * How can this regulatory hurdle be turned into a competitive advantage against slower rivals? * What are the most common pitfalls foreign manufacturers face when dealing with ANVISA's new rules? At Pure Global, we specialize in navigating these complexities. We provide end-to-end regulatory consulting, acting as your local representative and using advanced AI tools to ensure your technical dossiers are compliant and submitted efficiently. Don't let regulatory hurdles derail your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/.

Brazil's MedTech market just experienced a seismic shift. ANVISA, the national regulatory agency, has rolled out its new comprehensive framework, RDC 751, fundamentally changing the rules for medical device registration and market access. This move aligns Brazil closer than ever with international standards like the EU MDR. In this episode, we break down what this massive overhaul means for manufacturers. We dissect the new risk classification system, the updated submission pathways, and the critical changes to technical dossier requirements, providing a clear roadmap for anyone looking to enter or stay in Latin America's largest healthcare market. Imagine a MedTech scale-up from the United States with an innovative orthopedic implant. They viewed Brazil as a primary expansion target but were stuck. Their main pain point was the regulatory divergence. Their FDA and EU technical files required a complete, costly, and time-consuming overhaul for the old Brazilian system, creating a barrier of over 18 months of work before they could even submit. With the new RDC 751, the question now is: can their existing EU MDR dossier fast-track their entry, or are there hidden complexities in the new rules that could still derail their launch? Key Takeaways: * How do the new four risk classes under RDC 751 compare to the previous Brazilian system? * What specific documents from my EU MDR technical file can be repurposed for a Brazilian submission? * Is the simplified `notificação` pathway truly faster for Class I and II devices? * What are the new labeling and IFU requirements that manufacturers often overlook? * How has the definition of a "medical device family" changed for submissions? * What are the new obligations for the Brazil Registration Holder (BRH) under RDC 751? * Are there any new post-market surveillance requirements that come with this framework? At Pure Global, we specialize in demystifying complex regulatory changes like Brazil's RDC 751. We offer end-to-end solutions, from developing a tailored regulatory strategy to compiling your technical dossier and acting as your local Brazil Registration Holder. Our unique blend of local expertise and advanced AI tools streamlines your path to market access in over 30 countries. Don't let regulatory hurdles block your growth in LATAM. Contact us today at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can accelerate your success.

This week, we dissect the groundbreaking new resolution from Brazil's ANVISA, RDC 989, which establishes a new fast-track approval pathway for AI-driven diagnostic software. This is a pivotal moment for the MedTech industry in Latin America, promising to accelerate innovation and market access. However, this opportunity comes with significant new hurdles. The regulation introduces complex requirements for predetermined change control plans, mandates the use of local Brazilian patient data for algorithm validation, and enforces stricter cybersecurity protocols. We explore the strategic implications for foreign and domestic manufacturers aiming to capitalize on this new landscape. A real-world example. a U.S.-based SaMD company has its AI-powered radiological tool approved by the FDA. They targeted Brazil for their next expansion, but ANVISA's new RDC 989 just made their existing clinical data insufficient. They now face the urgent challenge of conducting a local validation study to qualify for the fast-track process, a costly and time-consuming roadblock they didn't anticipate. Key Takeaways: 1. What exactly is a Predetermined Change Control Plan (PCCP) and how do I create one for ANVISA? 2. Does my existing clinical data from US or EU studies meet the new requirements for Brazil? 3. What are the specific cybersecurity and data privacy mandates under RDC 989? 4. How can I initiate a local clinical validation study in Brazil efficiently? 5. What is the timeline for compliance for products already under review by ANVISA? 6. How does this new fast-track pathway change the overall cost and timeline for market entry? 7. Will this regulation give local Brazilian MedTech startups a competitive advantage? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local expertise with advanced AI and data tools to streamline global market access, helping you navigate complex regulations like RDC 989 to ensure your products reach the market efficiently. To understand how we can help with your market access strategy in Brazil and beyond, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Brazil's national regulatory agency, ANVISA, has unexpectedly accelerated the compliance deadlines for its Unique Device Identification (UDI) system, creating a significant new challenge for MedTech manufacturers. This sudden shift requires immediate action on labeling, data management, and submission strategies to avoid market disruption. While this presents a major hurdle, it also offers a competitive advantage to agile companies that can quickly adapt. This episode of LATAM MedTech Insights explores the specific details of ANVISA's new mandate, the potential pitfalls, and the strategic opportunities that arise from this regulatory surprise. **Case Study:** Imagine your company has a portfolio of high-risk cardiovascular devices thriving in the Brazilian market. Your team has been methodically preparing for a 2027 UDI compliance deadline. Suddenly, last week's ANVISA announcement pulls that deadline forward, demanding full compliance in just 18 months. Now you face an urgent crisis: redesigning all packaging, gathering extensive new data points, and navigating a complex database submission, all while your competitors are facing the same race against time. A single misstep could mean losing your registration and handing the market to a more prepared rival. **Key Takeaways:** * What are the exact new UDI compliance deadlines for different device classes in Brazil? * Why are the new data submission requirements more complex than just standard labeling? * How can this regulatory shift completely disrupt your current product roadmap and budget? * What are the immediate operational steps your company must take to avoid a market lockout? * Could this move by ANVISA trigger similar accelerated timelines in other LATAM countries? * Is your current local representative in Brazil equipped to handle this sudden change? * How can you turn this compliance crisis into a strategic advantage over your competitors? Struggling to make sense of new regulations in Latin America? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We combine local expertise in markets like Brazil with advanced AI tools to streamline your global market access, from regulatory strategy to technical dossier submission. Don't navigate the complexities alone. Contact Pure Global at info@pureglobal.com or visit https://pureglobal.com/ to secure your market presence.

This week, we dissect a sudden and significant regulatory enforcement shift from Brazil's ANVISA. The agency has accelerated the implementation of its comprehensive UDI traceability system for high-risk medical devices, a key part of its 2026-2027 agenda to harmonize with global standards. This move is catching many international manufacturers off guard, creating immediate challenges for market access and post-market compliance. We explore the concrete implications of this accelerated timeline, from rejected submissions due to data inconsistencies to new, stringent requirements for adverse event reporting. Consider a company that has spent years preparing its Class IV device for the Brazilian market. They believe their dossier is perfect, but their submission is rejected on day one. The reason is not a failure in the device's clinical data, but an administrative error in the UDI database submission, a new and complex requirement. This single misstep could delay their launch by over six months, costing millions in potential revenue. **Key Takeaways:** * What are the exact database requirements for the new UDI submissions under ANVISA's accelerated timeline? * How does this UDI enforcement align with the broader EU MDR harmonization trend in Brazil? * Which specific device classes are most at risk for submission delays right now? * What are the new post-market surveillance reporting requirements involving UDI data? * How can you validate your UDI data for ANVISA's system before making a formal submission? * What are the most common mistakes manufacturers are making with the new UDI requirements? * How should this change impact your budget and timeline for entering the Brazilian market? Navigating unexpected regulatory hurdles like these is where Pure Global excels. We provide end-to-end regulatory consulting for MedTech and IVD companies, leveraging our local expertise in Brazil and over 30 other markets. From developing an updated regulatory strategy to managing complex database submissions and ensuring post-market compliance, we streamline your path to market. Don't let regulatory surprises derail your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure your market access.

Brazil's regulatory agency, ANVISA, is launching a major digital overhaul for 2026, promising to slash approval times and streamline market access for medical devices. This episode dives into the core of ANVISA's new agenda, from the 'AnvisAI' project aimed at modernizing submissions to new fast-track queues for lower-risk devices. We explore how this digital transformation is creating unprecedented opportunities for MedTech innovators. For instance, a company with a cutting-edge AI diagnostic tool that once faced a multi-year waiting period now sees a viable path to market, evidenced by recent approvals of complex software. But this new speed comes with higher expectations, demanding alignment with stringent global standards. Key Questions This Episode Will Address: - How will ANVISA's 2026 digital agenda change your market entry strategy for Brazil? - Is your current technical dossier prepared for the new, stricter compliance framework? - What are the hidden risks of misclassifying your software under the new accelerated pathways? - How can the recent approval of AI imaging software serve as a roadmap for your submission? - Are you prepared to leverage these regulatory changes to get ahead of your competitors in LATAM's largest market? - What specific steps must you take to adapt your Quality Management System for Brazil's new landscape? At Pure Global, we provide end-to-end regulatory consulting to help MedTech and IVD companies navigate this evolving environment. We combine local expertise with advanced AI tools to streamline global market access. Let us be your local representative and strategic partner in over 30 markets. Contact us for a consultation at info@pureglobal.com or visit https://pureglobal.com/.

This week on LATAM MedTech Insights, we dissect the groundbreaking news from Brazil's ANVISA. A new fast-track approval pathway for AI-powered medical software has just been announced, promising to revolutionize market access in Latin America's largest market. This is the opportunity the industry has been waiting for, but it comes with a complex twist. This newfound speed is coupled with a formidable set of new cybersecurity and data privacy mandates, tailor-made for Brazil. We explore the hidden hurdles within this new regulation that could trip up even the most prepared global MedTech firms, turning a golden opportunity into a costly and time-consuming dead end. Here is a real-world scenario. Your company has developed a breakthrough AI diagnostic tool, and you are ready to conquer the Brazilian market. The new fast-track promises a swift approval, but your application is suddenly stalled. The reason? You overlooked an obscure new requirement for a Brazil-based Data Protection Officer, a critical detail buried deep in the new regulation. Now you face months of delays, unforeseen costs to restructure your local operations, and the constant threat of a competitor beating you to market. Key Takeaways for This Episode: - What are the specific device classifications that qualify for ANVISA's new SaMD fast-track? - How do the new Brazilian data privacy rules for MedTech differ from GDPR and HIPAA? - Is a local, Brazil-based Data Protection Officer now mandatory for all foreign SaMD manufacturers? - What are the three biggest cybersecurity vulnerabilities ANVISA will be auditing for in new submissions? - How can you leverage your existing technical dossier for this new, unique submission process? - What are the new requirements for post-market algorithm performance monitoring? - Could this new Brazilian framework become the regulatory blueprint for other LATAM countries? Navigating these regulatory shifts is what we do best. Pure Global transforms complexity into a competitive advantage. With our on-the-ground experts in Brazil and advanced AI-powered data tools, we provide end-to-end solutions for market access, from initial strategy and technical dossier submission to acting as your official local representative. Don't let regulatory hurdles block your entry into LATAM's most dynamic market. To ensure your AI MedTech product successfully navigates the new ANVISA landscape, contact us at info@pureglobal.com or visit https://pureglobal.com/ for a strategic consultation.

In a move that sent shockwaves through the MedTech industry, Brazil's regulatory agency, ANVISA, launched a mandatory new digital submission platform for high-risk medical devices last week. This sudden shift away from traditional paper-based systems has left many manufacturers scrambling to adapt. This episode of LATAM MedTech Insights unpacks the immediate fallout of this decision. We explore the technical hurdles, the hidden documentation requirements, and the strategic implications for companies aiming to enter or expand within Latin America's largest market. We'll look at the case of a cardiovascular device company whose critical product launch was jeopardized overnight by the new digital mandate. Their story highlights the severe financial and strategic costs of being unprepared for abrupt regulatory changes in Brazil. Key Questions Answered: 1. What are the three biggest technical mistakes companies make on the new ANVISA portal? 2. How does this digital shift affect submission timelines for Class III and IV devices? 3. Are there any unannounced changes to the technical dossier requirements? 4. How can you leverage this change to potentially speed up your approval process? 5. What does this move signal about ANVISA's long-term regulatory strategy? 6. Is your local distributor truly equipped to handle this level of regulatory complexity? 7. How will this impact foreign manufacturers compared to local Brazilian companies? At Pure Global, we specialize in navigating these complex regulatory landscapes. We offer end-to-end solutions for MedTech and IVD companies, acting as your local representative and using advanced AI tools to streamline technical submissions. Don't let regulatory surprises derail your market access strategy. Contact us for a consultation at info@pureglobal.com or learn more by visiting https://pureglobal.com/.

This week, we dive into a critical regulatory update from Brazil's ANVISA that is reshaping the landscape for digital health and Software as a Medical Device (SaMD). The new guidance introduces stringent requirements for AI technologies, cybersecurity, and local data management, catching many international MedTech companies off guard. We explore why existing FDA or CE Mark documentation is no longer enough for the Brazilian market. This episode breaks down the new rules and discusses how adapting to them can provide a significant competitive advantage in Latin America's largest and most lucrative MedTech market. **Case Study:** A U.S. startup with a cutting-edge AI diagnostic tool was poised to launch in Brazil. Despite having their clinical data and technical file ready, their submission was abruptly halted. The reason? It lacked a detailed cybersecurity vulnerability report adapted to Brazil's specific data privacy laws (LGPD). This unexpected roadblock could delay their launch by over a year, creating an opening for local competitors to seize market share. Are you prepared for this new reality? **Key Questions Answered:** * What specific cybersecurity standards has ANVISA now mandated for all SaMD products? * How does the new guidance re-classify your AI-powered medical software? * Are your existing clinical validation studies sufficient for the new Brazilian requirements? * What are the three most common documentation pitfalls for foreign firms under the new guidelines? * Why is appointing a local Brazil Registration Holder now more critical than ever? * How can you turn Brazil's tough new regulations into a strategic advantage? At Pure Global, we specialize in demystifying complex regulatory landscapes. Our local experts in Brazil, combined with our AI-driven data tools, provide end-to-end support for your MedTech and IVD products. We transform regulatory hurdles into market opportunities. Ready to accelerate your entry into Brazil? Contact us at info@pureglobal.com or visit https://pureglobal.com/.

This week on LATAM MedTech Insights, we explore the significant shift in Latin America's medical device industry. The region is rapidly moving from being a net importer to a powerful hub for local MedTech manufacturing. We unpack the key drivers behind this acceleration, including supply chain strategy, cost benefits, and new government incentives in major markets like Brazil and Mexico. We dive into the real-world challenges and opportunities this trend presents. We analyze the complex decision-making process for companies weighing the benefits of local production against the formidable regulatory hurdles set by agencies like ANVISA and COFEPRIS. It's a strategic gamble that could redefine market leadership in the region. What you'll learn in this episode: - Why are multinational MedTech companies suddenly prioritizing local manufacturing in Latin America? - What are the hidden regulatory costs of setting up a production line in Brazil versus Mexico? - How can a company leverage local manufacturing to gain a competitive advantage? - What is the number one mistake companies make when aligning with ANVISA's manufacturing practices? - Are local supplier networks in countries like Colombia and Costa Rica mature enough for complex devices? - How does in-country production change the strategy for post-market surveillance? - What specific government incentives are most attractive for new MedTech manufacturers in 2026? Navigating the transition to local manufacturing requires deep, on-the-ground expertise. Pure Global offers end-to-end regulatory solutions for MedTech companies, combining local experts with advanced AI tools to streamline market access. Whether you're developing a regulatory strategy for a new plant or registering your locally produced device, we act as your local representative in over 30 markets, including Brazil, Mexico, and Colombia. Let us help you turn complex regulatory challenges into a competitive advantage. Contact us at info@pureglobal.com or visit https://pureglobal.com/.

Brazil's health agency, ANVISA, has just introduced a stringent new cybersecurity regulation for all connected medical devices. This sudden move, aimed at enhancing patient safety and data protection, presents immediate and complex challenges for manufacturers. It escalates compliance costs and extends timelines, demanding a new level of technical documentation that many were not prepared for. This podcast episode breaks down what the new rules demand and explores the strategic implications for companies operating in Latin America's largest market. We analyze the specific requirements, the reasons behind this abrupt shift, and how it will reshape the competitive landscape for both local and international MedTech firms. **Key Takeaways:** * What are the three core technical requirements of ANVISA's new cybersecurity rule? * How does this new mandate affect devices already on the Brazilian market versus new submissions? * Why is this change happening now, and is it part of a larger LATAM regulatory trend? * What are the biggest compliance blind spots for foreign manufacturers entering Brazil? * Can proactive compliance with this new rule become a competitive advantage? * How will this impact the device registration timeline and budget for 2026? * What specific documentation, like a Software Bill of Materials, is now non-negotiable? Is your MedTech device ready for Brazil's new cybersecurity landscape? At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies. We combine local expertise with advanced AI to streamline your market access and ensure you stay ahead of critical changes like this. Don't let regulatory surprises derail your strategy. Contact Pure Global at info@pureglobal.com or visit us at https://pureglobal.com/.

This week, we dissect a groundbreaking regulatory shift in Latin America's largest market. Brazil's ANVISA has just unveiled a new, accelerated pathway for high-risk medical devices by recognizing approvals from major global agencies, signaling a major push to attract cutting-edge technology. But this speed comes with a hidden cost. The new framework also introduces some of the strictest post-market surveillance demands seen in the region. We explore the critical balance between rapid innovation and patient safety, and what this means for MedTech companies eyeing the Brazilian market. Imagine your company's AI-powered surgical device received FDA approval and can now use a fast-track process for Brazil. You cut your time-to-market by more than a year, but now ANVISA is demanding real-world performance data from Brazilian hospitals to validate its effectiveness locally. How do you leverage the speed of entry without getting buried in this new, intensive compliance burden? Key Takeaways: - What is the AREE reliance pathway and which foreign approvals does ANVISA now recognize? - How does this new rule change the submission strategy for Class III and IV devices in Brazil? - What are the unwritten expectations for post-market surveillance for fast-tracked devices? - How can you prepare a real-world data collection plan for the Brazilian market? - Does this regulatory shift in Brazil signal a wider trend across Latin America? - What are the biggest compliance risks for companies under this new paradigm? - How do you manage technical dossier requirements when leveraging a foreign approval? - What are the key operational costs associated with these new post-market rules? At Pure Global, we specialize in navigating these complex regulatory shifts. Our combination of local expertise and advanced AI tools helps MedTech and IVD companies streamline market access, from initial strategy to post-market surveillance. We turn regulatory hurdles into opportunities for growth. To learn how we can help you succeed in Brazil and over 30 other markets, contact us at info@pureglobal.com or visit https://pureglobal.com/.

This week, we dive into a critical regulatory update from Brazil. ANVISA has just rolled out a new resolution that reshapes the essential safety and performance requirements for medical devices, placing a heavy new emphasis on lifecycle risk management and international harmonization. This change impacts everything from technical file preparation to post-market surveillance. We explore the specific new requirements for high-risk devices, software, and the increased demand for locally relevant clinical data. This episode is essential for any MedTech company currently in or planning to enter the Brazilian market, as non-compliance with these new rules could lead to significant delays and rejections. **Case Study:** A European MedTech company, confident with their CE-marked cardiac monitoring software, submits to ANVISA. They are unexpectedly rejected. The reason? Their risk management file, which was perfectly acceptable for the EU, failed to meet Brazil's new, stringent requirements for post-market data collection and cybersecurity vulnerability monitoring. Their market entry is now delayed by at least a year, forcing a costly overhaul of their compliance documentation. **What You'll Learn:** - What specific event triggered ANVISA's major regulatory overhaul last week? - How does the new 'lifecycle' approach to risk management change your submission strategy? - Are your existing international clinical studies still valid under the new rules? - What are the three new documentation requirements for Software as a Medical Device (SaMD)? - Why might your current Quality Management System be non-compliant in Brazil right now? - What is the single biggest mistake foreign manufacturers are making in their new ANVISA submissions? At Pure Global, we specialize in navigating these complex regulatory landscapes. We offer end-to-end solutions, from market access strategy to local representation, using advanced data tools to streamline your path to compliance in over 30 markets, including Brazil. Don't let regulatory hurdles block your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can help.